ATE247488T1 - Immunotoxin enthaltend ein disulfid- stabilisiertes antikörperfragment - Google Patents

Immunotoxin enthaltend ein disulfid- stabilisiertes antikörperfragment

Info

Publication number
ATE247488T1
ATE247488T1 AT96934165T AT96934165T ATE247488T1 AT E247488 T1 ATE247488 T1 AT E247488T1 AT 96934165 T AT96934165 T AT 96934165T AT 96934165 T AT96934165 T AT 96934165T AT E247488 T1 ATE247488 T1 AT E247488T1
Authority
AT
Austria
Prior art keywords
antibody fragment
disulfide stabilized
stabilized antibody
immunotoxin
disulfide
Prior art date
Application number
AT96934165T
Other languages
English (en)
Inventor
Ira Pastan
Chien-Tsun Kuan
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE247488T1 publication Critical patent/ATE247488T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT96934165T 1995-10-13 1996-10-11 Immunotoxin enthaltend ein disulfid- stabilisiertes antikörperfragment ATE247488T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US538895P 1995-10-13 1995-10-13
PCT/US1996/016327 WO1997013529A1 (en) 1995-10-13 1996-10-11 Immunotoxin containing a disulfide-stabilized antibody fragment

Publications (1)

Publication Number Publication Date
ATE247488T1 true ATE247488T1 (de) 2003-09-15

Family

ID=21715593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96934165T ATE247488T1 (de) 1995-10-13 1996-10-11 Immunotoxin enthaltend ein disulfid- stabilisiertes antikörperfragment

Country Status (8)

Country Link
US (2) US5980895A (de)
EP (1) EP0861091B1 (de)
JP (1) JPH11513669A (de)
AT (1) ATE247488T1 (de)
AU (1) AU706056B2 (de)
CA (1) CA2234666A1 (de)
DE (1) DE69629580D1 (de)
WO (1) WO1997013529A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1000163B1 (de) * 1997-07-11 2005-10-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services Pseudomonas exotoxin-a-ähnliche chimerische immunogene
US7314632B1 (en) 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
WO1999064073A2 (en) * 1998-06-11 1999-12-16 The Government Of The United States, Represented By The Secretary Of The Department Of Health And Huan Services Recombinant immunotoxin directed against the hiv-1 gp120 envelope glycoprotein
ATE311199T1 (de) 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
PL357448A1 (en) * 2000-02-25 2004-07-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
US7314625B2 (en) * 2000-12-21 2008-01-01 The United States As Represented By The Secretary Of The Department Of Health And Human Services Chimeric protein comprising non-toxic Pseudomonas exotoxin A and Type IV pilin sequences
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1551453A4 (de) 2002-06-17 2007-04-25 Us Gov Health & Human Serv Spezifitätsgrafting eines mäuseantikörpers auf ein menschliches gerüst
SI1551876T1 (sl) 2002-10-16 2011-07-29 Purdue Pharma Lp Protitelesa, ki se vežejo na celično povezan CA 125/0722P, in postopki za njihovo uporabo
DK2829283T3 (en) 2003-04-30 2017-09-18 Univ Zuerich METHOD OF TREATING CANCER USING IMMUNOTOXIN
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
GB0320459D0 (en) * 2003-09-01 2003-10-01 Selective Antibodies Ltd Assay methods and materials
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
TWI293957B (en) * 2004-07-21 2008-03-01 Healthbanks Biotech Co Ltd A superantigen fusion protein and the use thereof
AU2005294436A1 (en) 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against Pseudomonas infection
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
EP2295080A3 (de) * 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-Zell-Verringerung mit CD37-spezifischen und CD20-spezifischen Bindungsmolekülen
US20090220501A1 (en) * 2006-01-30 2009-09-03 Fey Georg H Anti-CD19 Antibody, Immunotoxin and Treatment Method
US20070178103A1 (en) * 2006-01-30 2007-08-02 Fey Georg H CD19-specific immunotoxin and treatment method
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
CN101868246A (zh) * 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
JP2012533587A (ja) * 2009-07-22 2012-12-27 セニックス バイオサイエンス ゲーエムベーハー 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート
WO2012030949A2 (en) * 2010-09-01 2012-03-08 Kansas State University Research Foundation B2-glycoprotein i peptide inhibitors
JP6162606B2 (ja) 2011-01-14 2017-07-12 レッドウッド バイオサイエンス， インコーポレイテッド アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
CN102161998B (zh) * 2011-01-14 2013-01-09 中国人民解放军军事医学科学院附属医院 基于b7-1-pe40kdel外毒素融合基因的dna疫苗及其用途
MX2013012905A (es) * 2011-05-06 2014-04-25 Us Gov Health & Human Serv Inmunotoxina recombinante dirigida a la mesotelina.
EP2747781B1 (de) * 2011-08-23 2017-11-15 Roche Glycart AG Bispezifische antikörper spezifisch für t-zell-aktivierende antigene und ein tumorantigen sowie verwendungsverfahren
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
JP6578206B2 (ja) 2012-07-19 2019-09-18 レッドウッド バイオサイエンス， インコーポレイテッド Ｃｄ２２に特異的な抗体およびその使用方法
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
EP3184547A1 (de) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg-antikörper und verfahren zur verwendung
ES2908470T3 (es) 2015-11-09 2022-04-29 Scherer Technologies Llc R P Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
CA1341411C (en) * 1988-04-16 2002-12-17 Lutz Riechmann Method for producing fv fragments in eukaryotic cells
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
CA2116774C (en) * 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
JP3512795B2 (ja) * 1991-09-30 2004-03-31 アメリカ合衆国 組換免疫毒素
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity

Also Published As

Publication number Publication date
WO1997013529A1 (en) 1997-04-17
EP0861091B1 (de) 2003-08-20
JPH11513669A (ja) 1999-11-24
DE69629580D1 (de) 2003-09-25
AU7264496A (en) 1997-04-30
US6074644A (en) 2000-06-13
EP0861091A1 (de) 1998-09-02
CA2234666A1 (en) 1997-04-17
US5980895A (en) 1999-11-09
AU706056B2 (en) 1999-06-10

Similar Documents

Publication Publication Date Title
DE69629580D1 (de) Immunotoxin enthaltend ein disulfid-stabilisiertes antikörperfragment
PT804237E (pt) Anticorpos humanizados contra a molecula de adesao leucocitaria vla-4
IL132249A0 (en) Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
PT1087013E (pt) Imunoglobtainas desprovidas de cadeias leves
DE69532889D1 (de) Interleukin-5-spezifische rekombinante antikörper
FR2702543B1 (fr) Ensemble projecteur de route pour vehicules comportant un projecteur auxiliaire.
DK1489082T3 (da) Mellemprodukter
FR2703239B1 (fr) Agrafe pour prothèse inter-épineuse.
HUT74845A (en) Antibody purification
EP0597844A4 (de) Ziel-spezifische, zytotoxische, rekombinante exotoxine aus pseudomonas.
FR2699866B1 (fr) Ensemble anti-roulis pour véhicule.
ITMI961095A0 (it) Veicolo di accumulo per l'accumulo di materiale sfuso.
FR2702361B1 (fr) Fixateur pour les ostéosynthèses lombo-sacrées.
FR2701684B1 (fr) Ensemble d'amenée de fluide pour véhicule d'exploitation.
FR2716653B1 (fr) Ensemble projecteur-feu pour véhicule.
FR2742106B1 (fr) Phare pour vehicules
FR2675092B1 (fr) Ensemble de projecteurs pour vehicules.
FR2701833B1 (fr) Fixateur pour les ostéosynthèses lombo-sacrées.
FR2713746B1 (fr) Phare pour véhicules, comportant un diaphragme entourant partiellement la source lumineuse.
FR2735164B1 (fr) Glissiere de securite perfectionnee pour les routes ou analogues
FR2708237B1 (fr) Articulation pour siège de véhicule.
FR2699259B1 (fr) Projecteur de véhicule automobile comportant des moyens pour engendrer deux faisceaux différents à partir d'une même source et d'un même miroir.
DE69300527D1 (de) Dichtung für Automobil-Karrosserieteile.
FR2708296B1 (fr) Rail-piste pour voies de véhicules guidés.
KR970027294U (ko) 차량도장용 만능조사식 건조기

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties